Sale of UH biotech spin-off shows commercialization potential

December 11, 2008

HOUSTON, Dec. 11, 2008 - In a move that demonstrates the commercial appeal of research coming out of the University of Houston, a local company created by six of its professors was sold to a global conglomerate in the disease-research and drug-discovery industries.

VisiGen Biotechnologies Inc., a biotechnology company created by UH researchers working on a new process that will be used to sequence individual human genomes, was acquired for $20 million from Invitrogen Corp., which recently merged with Applied Biosystems to form Life Technologies (NASDAQ: LIFE). Acquired as a wholly owned subsidiary, VisiGen will continue to operate under the same name, with Life Technologies offering its strength as a global biotechnology tools company that accelerates such scientific exploration as personalized medicine, regenerative science and molecular diagnostics.

"This is a move that illustrates the commercial appeal of the research being done at the University of Houston," said John Bear, dean of UH's College of Natural Sciences and Mathematics. "Milestones such as this demonstrate how our scientists are impacting society, as well as helping to generate a stronger economy."

This is one of the largest acquisitions of a UH spin-off company in the university's history. Holding an equity share in VisiGen, UH will receive nearly half a million dollars from the initial installment of the deal.

"To have something like this get its start at UH is remarkable," Bear said. "In addition to the earliest experiments with this DNA sequencing technology being done on the UH campus before VisiGen moved to its own facilities, a collateral benefit of this spin-off to our university is that it provided a place for the training and employment of our graduates, with about half of VisiGen's employees being UH alumni."

VisiGen became one of Houston's leading biomolecular nanotechnology companies, undertaking research that is leading to the development of new technology for direct molecular sensing to sequence an entire genome - the genetic code in a person's DNA - in less than 24 hours at a reasonable cost. This and other developing technologies coming out of VisiGen hold promise for personalizing medicine, so that people can avoid risks to which they are particularly susceptible - such as diet-linked diseases and adverse reactions to some medications - and make choices likely to best promote their own health. For example, recent dramatic advances in the genomic study of cancer could be applied to individual patients' treatments by sequencing their particular cancer cells, allowing the best treatment to be used first.

The cost of the first human genome was nearly $3 billion, mostly due to the cost of a tremendous amount of technology development. The cost of sequencing a human genome has been falling rapidly since then, hitting a record-low price point of $60,000 in reagent costs with Applied Biosystems' SOLiD technology. Dramatically lowering the costs of whole genome sequencing will enable researchers to sequence genomes of potentially thousands of human subjects involved in studies to identify genes that contribute to specific, yet complex, diseases. The long-term goal is to cut the whole-genome sequencing cost to below $1,000, providing for applications in routine medical care and allowing doctors to tailor diagnoses, treatments and preventative measures to an individual's unique genetic profile.

The UH team at VisiGen achieved proof of concept, with this technology guided by a solid principle and success in the lab. The merger will provide the catalyst needed to bring it to market through the development of critical technologies made possible with the new resources available to its researchers.

VisiGen President and CEO Susan Hardin, a former biology and biochemistry professor at UH, will continue with VisiGen as research director. While their association with the company has ended, the five remaining UH researchers, who are credited with numerous patents resulting from VisiGen discoveries, will continue working on the development of technologies that will spur new discoveries, additional patents and possibly new spin-off companies.

Those remaining researchers at UH are James Briggs, associate professor of biology and biochemistry, chemical engineering and chemistry; Xiaolian Gao, professor of biology and biochemistry and professor of chemistry; Michael Rea, professor of biology and biochemistry; Shiao-Chun (David) Tu, John and Rebecca Moores Professor of biology and biochemistry and professor of chemistry; and Richard Willson, professor of chemical and biomolecular engineering and biology and biochemistry.

"This team exemplifies how top-tier success requires interdisciplinary collaborations," said Donald L. Birx, vice chancellor for research for the UH System and vice president for research for UH. "With researchers from four different specialties working together to share their respective areas of expertise, this is a prime example of what it takes to solve the challenges of the 21st century and propel the university's projects toward commercialization."
-end-
About the University of Houston

The University of Houston, Texas' premier metropolitan research and teaching institution, is home to more than 40 research centers and institutes and sponsors more than 300 partnerships with corporate, civic and governmental entities. UH, the most diverse research university in the country, stands at the forefront of education, research and service with more than 36,000 students.

For more information about UH, visit the university's Newsroom at http://www.uh.edu/news-events/.

To receive UH science news via e-mail, visit http://www.uh.edu/news-events/mailing-lists/sciencelistserv.php.

University of Houston

Related Human Genome Articles from Brightsurf:

240 mammals help us understand the human genome
A large international consortium led by scientists at Uppsala University and the Broad Institute of MIT and Harvard has sequenced the genome of 130 mammals and analysed the data together with 110 existing genomes to allow scientist to identify which are the important positions in the DNA.

The National Human Genome Research Institute publishes new vision for human genomics
The National Human Genome Research Institute this week published its 'Strategic vision for improving human health at The Forefront of Genomics' in the journal Nature.

Interpreting the human genome's instruction manual
Berkeley Lab bioscientists are part of a nationwide research project, called ENCODE, that has generated a detailed atlas of the molecular elements that regulate our genes.

3-D shape of human genome essential for robust inflammatory response
The three-dimensional structure of the human genome is essential for providing a rapid and robust inflammatory response but is surprisingly not vital for reprogramming one cell type into another.

The genome of chimpanzees and gorillas could help to better understand human tumors
A new study by researchers from the Institute of Evolutionary Biology (IBE), a joint center of UPF and the Spanish National Research Council (CSIC), shows that, surprisingly, the distribution of mutations in human tumors is more similar to that of chimpanzees and gorillas than that of humans.

It's in our genome: Uncovering clues to longevity from human genetics
Researchers from Osaka University found that high blood pressure and obesity are the strongest factors reducing lifespan based on genetic and clinical information of 700,000 patients in the UK, Finland and Japan.

New limits to functional portion of human genome reported
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.

Synthesizing the human genome from scratch
For the past 15 years, synthetic biologists have been figuring out how to synthesize an organism's complete set of DNA, including all of its genes.

Science and legal experts debate future uses and impact of human genome editing in Gender & the Genome
Precise, economical genome editing tools such as CRISPR have made it possible to make targeted changes in genes, which could be applied to human embryos to correct mutations, prevent disease, or alter traits.

Evolution purged many Neanderthal genes from human genome
Neanderthal genetic material is found in only small amounts in the genomes of modern humans because, after interbreeding, natural selection removed large numbers of weakly deleterious Neanderthal gene variants, according to a study by Ivan Juric and colleagues at the University of California, Davis, published Nov.

Read More: Human Genome News and Human Genome Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.